Literature DB >> 28471000

Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles.

Farzaneh Javan1, Alireza Vatanara1, Kayhan Azadmanesh2, Mohsen Nabi-Meibodi3, Mehdi Shakouri2.   

Abstract

OBJECTIVES: In this study, ritonavir was entrapped into solid lipid nanoparticles (SLNs) employing two production methods. The prepared SLNs were characterized and antiretroviral activity was investigated for more efficient formulation.
METHODS: Ritonavir-loaded SLNs were produced by solvent emulsification evaporation (SE) and double emulsion methods (DE), and the effects of Tween80 and poloxamer188 as external phase surfactant were compared. Prepared SLNs were characterized in terms of size, surface charge, entrapment efficiency (EE), release profile and thermal behaviour. Moreover, the activity of drug-loaded SLNs was investigated on the lentiviral-based pseudo-HIV-1 particles. KEY
FINDINGS: The average size of negatively charged SLNs was 170-250 nm with polydispersity index (PDI) of 0.2. The most EE% was about 53.2% achieved by DE method in the presence of poloxamer188. It was found that addition of poloxamer188 in the process led to increased entrapment efficiency and particle size. The in-vitro antiviral experiment showed ritonavir SLNs can actively maintain inhibition of virus production as well as free drug.
CONCLUSIONS: In this study, we showed the SLNs not only can encapsulate ritonavir efficiently but also can maintain its antiviral activity and modulate drug release as promising nanocarrier.
© 2017 Royal Pharmaceutical Society.

Entities:  

Keywords:  human immunodeficiency virus; ritonavir; solid lipid nanoparticles; vesicular stomatitis virus glycoprotein pseudo-typed HIV-1

Mesh:

Substances:

Year:  2017        PMID: 28471000     DOI: 10.1111/jphp.12737

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

Review 1.  Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Authors:  Yu Gao; John C Kraft; Danni Yu; Rodney J Y Ho
Journal:  Eur J Pharm Biopharm       Date:  2018-04-17       Impact factor: 5.571

2.  Advances in Antiviral Material Development.

Authors:  Lili Liang; Ashiq Ahamed; Liya Ge; Xiaoxu Fu; Grzegorz Lisak
Journal:  Chempluschem       Date:  2020-08-21       Impact factor: 3.210

Review 3.  Nano-based approach to combat emerging viral (NIPAH virus) infection.

Authors:  Rout George Kerry; Santosh Malik; Yisehak Tsegaye Redda; Sabuj Sahoo; Jayanta Kumar Patra; Sanatan Majhi
Journal:  Nanomedicine       Date:  2019-03-21       Impact factor: 5.307

Review 4.  Nanotechnology for virus treatment.

Authors:  Jiarong Zhou; Nishta Krishnan; Yao Jiang; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Today       Date:  2020-12-01       Impact factor: 20.722

Review 5.  Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems.

Authors:  Osama A Madkhali
Journal:  Molecules       Date:  2022-02-24       Impact factor: 4.411

Review 6.  Nanoparticles in clinical trials of COVID-19: An update.

Authors:  Abdur Rauf; Tareq Abu-Izneid; Anees Ahmed Khalil; Nabia Hafeez; Ahmed Olatunde; Mominur Rahman; Prabhakar Semwal; Yahya Saleh Al-Awthan; Omar Salem Bahattab; Ishaq N Khan; Muhammad Arslan Khan; Rohit Sharma
Journal:  Int J Surg       Date:  2022-08-08       Impact factor: 13.400

7.  Nanogold Particles Suppresses 5-Flurouracil-Induced Renal Injury: An Insight into the Modulation of Nrf-2 and Its Downstream Targets, HO-1 and γ-GCS.

Authors:  Mohamed El-Sherbiny; Eslam K Fahmy; Nada H Eisa; Eman Said; Hany A Elkattawy; Hasnaa Ali Ebrahim; Nehal M Elsherbiny; Fatma M Ghoneim
Journal:  Molecules       Date:  2021-12-19       Impact factor: 4.411

Review 8.  Antiviral therapies: advances and perspectives.

Authors:  Bruna Carolina Gonçalves; Mário Gabriel Lopes Barbosa; Anna Paula Silva Olak; Natalia Belebecha Terezo; Leticia Nishi; Maria Angélica Watanabe; Poliana Marinello; Daniele Zendrini Rechenchoski; Sergio Paulo Dejato Rocha; Lígia Carla Faccin-Galhardi
Journal:  Fundam Clin Pharmacol       Date:  2020-11-08       Impact factor: 2.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.